[1]headache, dryness of the mouth, nose and throat, blurred vision, tachycardia, urinary retention, constipation, restlessness, nervousness, insomnia, auditory and visual hallucinations have been reported, particularly when dosage recommendations have been exceeded.
Other Central Nervous System effects which have been reported rarely include dystonia, dyskinesia, extrapyramidal motor disturbances, tremor, twitching, muscle spasms, convulsions, disorientation, dizziness, decreased consciousness transient speech disorders, hypertension and paraesthesia.
Rare reports of cholestatic hepatitis and hypersensitivity reactions, including anaphylaxis, angioedema, allergic skin reactions and bronchospasm have been reported in association with cyclizine. There have also been a few reports of fixed drug eruption (rash), apnoea, generalised chorea, hypersensitivity hepatitis, hepatic dysfunction and agranulocytosis.
Anaphylaxis has been reported following intravenous administration of cyclizine co-administered in the same syringe as propanidid.
Anaphylactic shock is a rare adverse reaction to morphine.
A case of hyperactivity following intravenous administration of morphine during induction of anaesthesia has been reported.
A case of morphine-induced thrombocytopenia has been reported.
Morphine has a depressant effect on gonadal hormone secretion which can result in a reduction of testosterone leading to regression of secondary sexual characteristics in men on long-term therapy.
[2]Injection site reactions including vein tracking, erythema, pain and thrombophlebitis have been reported rarely.
Cyclimorph IV injection has demonstrated significant incidence of single cough or paroxysm of coughing immediately after its administration.
